Journal
NANOMEDICINE
Volume 8, Issue 9, Pages 1429-1442Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.12.180
Keywords
albumin; breast cancer; lapatinib; lipoprotein-like nanoparticle
Funding
- National Basic Research Program of China (973 Program) [2013CB932500]
- National Science and Technology Major Project [2012ZX09304004]
- Special Project for Nanotechnology from Shanghai [12nm0501500]
Ask authors/readers for more resources
Aim: The poor water solubility of many active compounds is a serious deterrent to their use as commercial drugs. Lapatinib is a dual inhibitor of the EGF receptor and EGF receptor 2 approved by the US FDA to treat advanced breast cancer. This study prepares lapatinib-incorporated lipoprotein-like nanoparticles (LTNPs) to enhance the water solubility and elevate the anti-tumor effect of lapatinib. Materials & methods: Bovine albumin was used to bind with lapatinib, and egg yolk lecithin was used to stabilize the conjugation of bovine albumin and lapatinib. The characteristics of LTNPs were evaluated by several experiments. Cell uptake and toxicity were performed on BT-474 cells. In vivo anti-tumor effect was performed on BT-474 xenograft-bearing mice. Results: LTNPs contained a lipid corona and a core of lapatinib and albumin. LTNPs could be effectively taken up by BT-474 cells and induced apoptosis. An in vivo study demonstrated that LTNPs could passively distribute into a tumor via the enhanced permeability and retention effect and induce anti-tumor activity in breast cancer. Conclusion: The authors present a convenient nanoformulation with improved anti-tumor effect, which is a promising candidate for clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available